Open AccessChanges in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo‐controlled, double‐blind clinical trials
Author(s) -
Sano Motoaki,
Chen Shi,
Imazeki Hisae,
Ochiai Hidekazu,
Seino Yutaka
Publication year - 2018
Publication title -
journal of diabetes investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.089
H-Index - 50
eISSN - 2040-1124
pISSN - 2040-1116
DOI - 10.1111/jdi.12726
Subject(s) - medicine , diabetes mellitus , type 2 diabetes mellitus , placebo , heart rate , clinical trial , cardiology , type 2 diabetes , endocrinology , blood pressure , alternative medicine , pathology
We evaluated the changes in heart rate on the treatment with SGLT2 inhibitor, luseogliflozin, in Japanese patients with type 2 diabetes mellitus (T2DM). It is suggested that luseogliflozin can effectively decrease in heart rate in patients with higher baseline.